Denosumab Has Edge on Alendronate for Steroid-Induced Bone Loss Denosumab Has Edge on Alendronate for Steroid-Induced Bone Loss

Long-term glucocorticoid users see greater gains in spine bone-mineral density when treated with the monoclonal antibody denosumab versus oral alendronate, a small clinical trial shows.Reuters Health Information
Source: Medscape Orthopaedics Headlines - Category: Orthopaedics Tags: Rheumatology News Source Type: news